Enlivex to Present at the 37th Annual Meeting of the Society For Immunotherapy Of Cancer

Rhea-AI Summary

Enlivex Therapeutics (Nasdaq: ENLV) announced a poster presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer from November 8-12, 2022, in Boston. The presentation titled “Synergistic anti-tumor effect of Allocetra–OTS, a cellular immune-therapy” is scheduled for November 10 and 11. Enlivex focuses on immunotherapy with its product Allocetra™, designed to reprogram macrophages to enhance immune response against cancer. For conference registration, visit the provided link.

Nes-Ziona, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced a poster presentation at the 37^th Annual Meeting of the Society For Immunotherapy Of Cancer, which is taking place both virtually and in-person from November 8, 2022 through November 12, 2022 in Boston, Massachusetts.

Enlivex’s presentation, “Synergistic anti-tumor effect of Allocetra–OTS, a cellular immune-therapy, in combination with immune checkpoint inhibitors/chemotherapy/CAR T, through in-vivo reprogramming of macrophages”, will take place on both November 10^th and 11^th, 2022. Those interested in registering for the conference can do so here.

ABOUT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member society of medical professionals dedicated to advancing cancer immunotherapy and biological therapy through its initiatives, educational sessions, and collaborative endeavors.

ABOUT ENLIVEX

Enlivex is a clinical stage immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit http://www.enlivex.com.

Safe Harbor Statement:  This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could,” “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA^TM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA^TM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.

ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivexpharm.com

INVESTOR RELATIONS CONTACT
Eric Ribner
LifeSci Advisors
eric@lifesciadvisors.com

                                                                                               

FAQ

What is the focus of Enlivex Therapeutics and its product Allocetra?

Enlivex Therapeutics specializes in macrophage reprogramming immunotherapy, developing Allocetra™, a cell therapy aimed at resetting non-homeostatic macrophages to boost the immune response against cancer.

When is the Society for Immunotherapy of Cancer meeting where Enlivex will present?

The Society for Immunotherapy of Cancer meeting is taking place from November 8 to November 12, 2022, in Boston.

What is the title of Enlivex's presentation at the SITC meeting?

The title of Enlivex's presentation is 'Synergistic anti-tumor effect of Allocetra–OTS, a cellular immune-therapy.'

On which dates will Enlivex present at the SITC meeting?

Enlivex will present on November 10 and 11, 2022.

How can I register for the Society for Immunotherapy of Cancer conference?

You can register for the conference by following the link provided in the press release.